Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2012

View Archived Issues

New S1P1 receptor agonists prepared by Allergan

Novel PI3K-alpha/mTORC1 inhibitors disclosed by Exelixis

Phase III study planned for MOD-4023

Novo Nordisk presents new long-acting drug for growth hormone deficiency

Lilly diabetes drug substantially decreases HbA1c without delaying recovery from hypoglycemia

Amicus reports preliminary results from phase II study in Pompe's disease

AstraZeneca patents novel agents for arrhythmia

Novel TRPV1 channel antagonists developed at GlaxoSmithKline

Polish team describes new fusion proteins for cancer

Korean researchers present novel protein kinase inhibitors

Merck KGaA designs new hPDK1 inhibitors

New fusion proteins for bone disorders designed in Korea

Research collaboration begins for Parkinson's disease gene therapy

EMA issues scientific opinion on Sanofi Pasteur vaccine

QRxPharma receives complete response letter for MoxDuo

Topica launches phase IIb/III study in onychomycosis

Dosing begins in first-in-human PA-401 trial

New gevokizumab trials initiated in uveitis and erosive osteoarthritis

FDA issues safety communication on cefepime

Depomed acquires rights to liquid-filled capsule analgesic

FDA approves first new weight loss drug in 13 years

Sunesis Pharmaceuticals receives milestone payment for kinase inhibitor program

PTC Therapeutics begins open-label ataluren study

FDA grants premarket approval to noninvasive test to detect prostate cancer

Janssen-Cilag applies for European approval of canagliflozin

CHMP issues opinion on Zyclara MAA

FDA issues complete response letter for Xarelto sNDA

Favorable preclinical profile supports clinical testing of grass pollen vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...